Loading...
Loading...
NKTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 2.3M |
| Gross Profit | -2.3M |
| Operating Expense | 30.7M |
| Operating I/L | -30.7M |
| Other Income/Expense | 5.7M |
| Interest Income | 5.7M |
| Pretax | -25.0M |
| Income Tax Expense | -2.3M |
| Net Income/Loss | -25.0M |
Nkarta, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of cell therapies for cancer treatment. Their approach involves utilizing chimeric antigen receptors on natural killer (NK) cells to recognize specific proteins on tumor cells. Their lead product candidates include NKX101, currently in Phase I clinical trials for relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product targeting B cell malignancies by focusing on the CD19 antigen. Nkarta, Inc. generates revenue through the development and potential commercialization of these innovative cell therapies for cancer treatment.
